溶葡球菌酶的抗菌活性研究进展  

Advances in anti-staphylococcal agent lysostaphin

作　　者：杨信怡[1] 游雪甫[1] 蒋建东[1] 

机构地区：[1]中国医学科学院中国协和医科大学医药生物技术研究所,北京100050

出　　处：《中国新药杂志》2005年第9期1113-1117,共5页Chinese Journal of New Drugs

基　　金：国家十五重大科技专项资助项目(2003AA2Z347D)

摘　　要：溶葡球菌酶是一种最初从模仿葡萄球菌培养物中分离出来的含Zn2+金属蛋白酶,具有良好的体内、外抗葡萄球菌活性,可能成为一种新型抗葡萄球菌感染药物。从药效学、药动学以及人体治疗等方面综述了溶葡球菌酶抗菌活性的研究进展,并展望其临床应用前景。Lysostaphin is a Zn^2＋ metalloproteinase initially isolated from S. simulan culture with favorable activity against staphylococci in vivo. The enzyme is currently evaluated as a potential antibacterial therapeutic for the pathogen infections. In this paper, the study progresses of lysostaphin in pharmacodynamics, pharmacokinetics and clinical therapeutics were reviewed. The potential clinical indications were explored.

关 键 词：溶葡球菌酶 药效学 药动学 人体治疗 

分 类 号：R977.3[医药卫生—药品] R515[医药卫生—药学]